drugset / Trial / NCT00533520
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
Timeline
- Start
- 2007-09
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | — |
| Comparator | Ranibizumab | Monoclonal antibody | 1 mg | — |
| Comparator | Ranibizumab | Monoclonal antibody | 2 mg | — |